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The effectiveness of fucoxanthin or kombu extract has been investigated in in vitro and in vivo studies as well as in clinical trials; however, the effectiveness of dried kombu has not been tested well, especially in clinical trials. "Harudori-kombu" is young kombu harvested in spring, whereas mature kombu is typically harvested in summer. Harudori-kombu is easy to consume owing to its soft texture; thus, the intake of effective amounts of bioactive components is enabled, which can be tested in clinical trials.
Therefore, we conducted a randomized, double-blind, placebo-controlled, parallel-group study to evaluate effects of the intake of dried Harudori-kombu in healthy subjects.
METHODS

Study design
The clinical study was conducted as a placebo-controlled, randomized, double-blinded, and parallel-group study in Hokkaido Information University, Health Information Science Research Center (Ebetsu city, Hokkaido, Japan). Schedule for the study is summarized in Table 1 . Written informed consent was obtained from subjects before their enrollment at visit 1. Subsequently, medical interviews, vital sign examinations, and hematological and biological assessments were performed at visits 2 (week 0; baseline), 3 (week 2; excluding adiponectin), and 4 (week 6); body composition measurements were performed at visits 2 and 4 alone. In addition, all subjects completed the Food Frequency Questionnaire Based on Food groups (FFQg) (Kenpakusha, Tokyo, Japan) at visits 2 and 4. During the entire course of this trial, subjects were asked not to change their daily activities, including food consumption and exercise habits. Subjects recorded their daily activities in a diary, and the records were reviewed by a medical doctor or nurse at each visit.
Primary outcome was lipid profiles, including total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C), triglyceride (TG), LDL-C/HDL-C ratio, and non-HDL. Secondary outcomes were body composition, including BW; body fat rate; BMI and waist circumference; adiponectin; blood pressure; and blood glucose profiles, including fasting plasma glucose (FPG), HbA1c, insulin, and homeostasis model assessment of insulin resistance (HOMA-IR). The efficacy of active test food was evaluated at week 6 and its safety at weeks 2 and 6. 
Study subjects
A total of 140 subjects volunteered to participate in the screening examination at visit 1. All volunteers provided written informed consent to participate in this clinical study. Through screening tests, 70 healthy Japanese subjects we enrolled (age ≥ 30 to < 70 years; LDL-C ≥ 120 to < 160 mg/dL; and BMI ≥ 22 to <30 kg/m 2 ). Inclusion and exclusion criteria are summarized in Table 2 . The eligible subjects were randomly assigned to one of two groups: the active test food (Harudori-kombu) group or the placebo group, stratified by sex, age, LDL-C, and BMI at visit 1.
Assignments were computer-generated using stratified block randomization at a third-party data center (Media Educational Center, Hokkaido Institute of Information Technology, Ebetsu city, Hokkaido). Medical doctors, nurses, clinical research coordinators, and statistical analysts were blinded to assignment information during the trial period. The information was only disclosed after the laboratory and analytical data were collected and the method of statistical analysis was finalized. 
Preparation of the test food
The manufacture of dried Harudori-kombu powder is detailed here. First, Ma-kombu (Saccharina japonica ver. japonica) was harvested in Hakodate (Hokkaido, Japan) and was used for preparing kombu samples. Second, raw kombu was boiled for a few minutes in seawater after harvesting and salted for a few days. Third, the salted kombu was washed, dried, and crushed. Finally, the coarse powder was ground into a fine powder, and 2.0 g of the powder was encapsulated in a gelatin capsule. The intake level of active test food was determined with reference to the intake level of fucoxanthin at previous trials (1-3 mg/day) [5, 6] . Placebo capsules contained dextrin powder instead of kombu powder. Nutrient compositions of the active test and placebo foods used in this study are presented in Table 3 . Fucoxanthin levels were analyzed using high-performance liquid chromatography. Nutrient composition analyses were performed using the methods established by the Japan Food Research Laboratories (Hokkaido, Japan). The active test and placebo foods were manufactured under strict quality control protocols and were identical in appearance. Ltd., Kyoto, Japan), respectively.
Food frequency questionnaire
FFQg was used for estimating nutrient intake from the regular diet of subjects. This questionnaire comprised 29 food groups and 10 types of cooking methods. For each question, the subjects reported the amount and frequency of food intake on a weekly basis. Based on the answers, regular and nutrient intakes (calories, protein, fat, carbohydrates, dietary fiber, and salt) were estimated.
Ethics
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Statistical analysis
Means and standard deviations of subject characteristics were calculated for each group. For the primary and secondary outcomes and food frequency questionnaire, values were analyzed using Student's t-test by comparing the means between the two groups. For subject characteristics, Fisher's exact probability test was used for sex and Mann-Whitney U-test was used for intake rate; student's t-test was used for the other subject characteristics. All statistical analyses were performed using SPSS Statistics 20 (IBM Japan, Ltd., Tokyo, Japan), and p < 0.05 was considered significant, while 0.05 ≤ p < 0.10 was considered tending towards significance.
Sample size
The sample size was statistically determined to obtain a power of 80% and a two-sided significance level of 5%. To demonstrate a difference in LDL-C at week 6, which was postulated to have an intergroup difference of 10 mg/dL with a standard deviation of 13 mg/dL, a sample size of 60 (30 in each group) was required. Assuming a 15% loss in the follow-up rate, 70 subjects (35 in each group) were enrolled.
RESULTS
Subject dropouts and characteristics
The flow of subjects' involvement through the trial is presented in Figure 1 . Subjects who provided informed consent (n = 140) were assessed for eligibility, and a total of 70 subjects were enrolled in this study. All enrolled subjects were randomized to one of the two intervention groups (placebo group, n = 35; active test food group, n = 35). One subject dropped out for personal reasons before the trial started; one subject dropped out because of elevated liver function markers at week 0 (before the test food intake), and two subjects dropped out for personal reasons during the test food intake period. Finally, 66 subjects completed this trial: 31 in the active test food group and 35 in the placebo group. All subjects were included in the safety analysis. The efficacy analysis included 31 subjects in the active test food group and 35 in the placebo group.
Sex ratio, mean age, height, BW, body fat rate, BMI, LDL-C, and intake rate for each group are presented in Table 4 . These characteristics did not significantly differ between the two groups, confirming the appropriate allocation of subjects between the active test food and placebo groups. Values are shown as mean and standard deviation. Fisher's exact probability test was used for sex, and
Mann-Whitney U-test was used for intake rate; student's t-test was used for the other characteristics. n, number of subjects; LDL-C: low-density lipoprotein cholesterol
Efficacy of Harudori-kombu on lipid profile
Effects of Harudori-kombu on lipid profile, including TC, LDL-C, HDL-C, TG, LDL-C/HDL-C ratio, and non-HDL, are summarized in (Table 5 ). There were no differences between the active test food and placebo groups in terms of changes in any of the parameters. 
Efficacy of Harudori-kombu on body composition and adiponectin levels
To confirm effects of Harudori-kombu on body composition, changes in BW, body fat rate, BMI, and waist circumference were evaluated (Table 6 ). In addition, effects of Harudori-kombu on adiponectin levels were assessed ( Table 6 ). The intake of active test food tended to improve body fat rate compared with the intake of placebo (Δweek6: Placebo, −0.1 ± 0.8%; active, −0.6 ± 1.2%; p = 0.055) [ Figure 2 -(a)]. Additionally, adiponectin level was improved in the active test food group compared with that in the placebo group at week 6 (Δ week 6: Placebo, −0.3 ± 1.3 µg/mL; active, 0.3±1.0 µg/mL; p = 0.034) (Figure 2-b) . BW, BMI, and waist circumference did not differ between the two groups. 
Efficacy of Harudori-kombu on blood pressure and blood glucose profile
We examined blood pressure (systolic and diastolic) and blood glucose profile (FPG, Insulin, HbA1c, and HOMA-IR). There were no statistically significant differences between the active test food and placebo groups (Table 6 ). 
Assessment of dietary nutrients of subjects during trial
The subjects completed FFQg at weeks 0 and 6 to assess dietary nutrients. Analysis revealed no statistically significant differences in intake of calories, proteins, lipids, carbohydrates, dietary fibers, and salt in dietary meal between the active test food and placebo groups ( Table 7) . These results suggest that dietary nutrients from the meals did not affect the results of this trial. 
Safety
For the safety analysis of active test food (Harudori-kombu), pulse rate; complete blood counts (WBC, RBC, Hb, Ht, and Plt); liver function (AST, ALT, γ-GTP, ALP, and LDH); and renal function (BUN, CRE, and UA) were evaluated. Minimal changes (Table 8 ) and minimal adverse effects (variation of clinical data and clinical observation) were observed in each group. In the active test food group, the five adverse effects were observed: diarrhea (n = 1); variation in LDH value (n = 2); variation in γ-GTP value (n =1); and variation in UA value (n =1). In the placebo group, nine adverse effects were observed: toothache (n = 1); urticarial (n = 1); variation in γ-GTP value (n = 2); variation in UA (n = 2); variation in CRE value (n = 1); variation in BUN (n = 1);
and variation in WBC (n = 1). However, regarding clinical observation, these subjects presented with only mild symptoms, and all recovered within a few days. Regarding variation of clinical data, these subjects presented with no symptoms related to variation; the principal investigator judged that none of the adverse events were related to the intake of the test food. Thus, the intake of Harudori-kombu had no or minimal unfavorable effects even at a dose of 17 g/day (as raw kombu). 
DISCUSSION
In this clinical trial, we assessed the effect of daily Harudori-kombu intake for 6 weeks on lipid profile, secondary body fat rate, adipokine levels, blood glucose profile, and blood pressure. We demonstrated that Harudori-kombu intake tended to reduce body fat rate and altered adiponectin levels.
The primary outcomes of changes in the lipid profile (TC, LDL-C, HDL-C, TG, LDL-C/HDL-C ratio, and non-HDL) were not significantly different between the active test food and placebo groups. Therefore, intake duration and/or the dose of Harudori-kombu should be reconsidered.
The secondary outcome of body fat rate tended to be reduced by the intake of active test food.
A previous clinical trial has demonstrated that the intake of fucoxanthin (1-3 mg/day) for 4 weeks reduced BW, BMI, and visceral fat in subjects with class 1 obesity compared with placebo [5] . In another study, Xanthigen ® (brown marine algae fucoxanthin + pomegranate seed oil) intake reduced BW in obese non-diabetic women [14] . In addition, active test food in our study increased adiponectin levels. The biological mechanism of body fat reduction by fucoxanthin depends on increased UCP-1 expression at the membranes of white adipose cells, likely mediated by increase in β3 adrenaline receptor (β3AR) expression [7] . Peroxisome proliferator-activated receptor γ (PPARγ) is downstream of β3AR and targets adiponectin [15, 16] . Similar to other natural products such as Cyclolepis genistoides D. Don (palo azul), fucoxanthin may increase adiponectin expression via PPARγ activation [17] . Adiponectin level decreases as visceral fat increases [18] .
Collectively, these results indicate that Harudori-kombu reduces body fat rate via UCP-1 or PPARγ activation, both of which elevate adiponectin levels.
In this clinical trial, we observed no effect of Harudori-kombu on blood glucose profiles. A previous clinical trial has demonstrated a significant decline in HbA1c levels in the 2 mg/day fucoxanthin group compared with that in the placebo group [6] . Moreover, adiponectin levels were associated with blood glucose profiles, such as insulin resistance and glucose uptake. Of note, obesity is an important component that exacerbates insulin resistance, and insulin resistance is often associated with increased body weight. In addition, various adipokines, such as adiponectin and resistin, are associated with insulin resistance [19] . In our clinical trial, subjects' initial FPG was normal and intake period was shorter than those in a previous trial [6] . These differences might explain unchanged blood glucose profiles in our study population.
Kombu is a rich source of dietary fibers, which confer various beneficial effects [20] .
Compared with a previous trial assessing the benefits of ingesting 5-10 g of dietary fiber, active test food of our study contributed to 1 g of dietary fiber per day, suggesting that the main functional component of active test food was fucoxantin.
In this study, no side effects or severe adverse events were observed during physical and blood examinations or reported in the medical interviews. These results confirm the safety of 6-week intake of 2.0 g of Harudori-kombu daily (as dried kombu). This study included healthy subjects who had not been receiving any medications for obesity, dyslipidemia, and/or diabetes mellitus. In addition, the intake periods in this study were short. In the future, investigation of the effects of Harudori-kombu with longer intake periods is required.
CONCLUSION
In this 6-week randomized, double-blinded, placebo-controlled, parallel-group comparative study, Harudori-kombu intake improved adiponectin levels and reduced body fat. Additionally, we confirmed the safety of Harudori-kombu over 6 weeks. Kombu is an important component of the Japanese diet, and our findings support the use of Harudori-kombu as a functional food with health benefits. 
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